Topic

VEEV

A collection of 12 issues

Veeva 2Q’26: "SaaSpocalypse" Cancelled

Early this year when most investors were grappling with “SaaSpocalypse”, I started buying Veeva when the stock was trading at $220. As the SaaSpocalypse mania spread like a virus in investors minds, Veeva stock went into a tailspin for a few months. As I averaged down a couple of times

Veeva 1Q'26: Strong Present, Patient Future

Programming Note: Some of you may have missed my announcement in my last post that I would be taking a couple of weeks break and reached out to see if everything is okay. Thank you for your concern, and I am back to daily posting schedule. Just a small note

"Never Sell" Episode: AI Doom, Veeva, Research and Writing

For the “Never Sell” podcast, Scuttleblurb and I published a new episode covering investors’ increasing fascination around AI doom scenarios, why we think Veeva is likely to be more insulated from AI disruption, and the value of approaching investment research more as a judge rather than as a lawyer defending

Veeva Model Update

As I have promised earlier, I have updated my Veeva model yesterday. If you are not familiar with the company, I suggest you read my Deep Dive (September 2024), and an update on the company from December last year. I will briefly go through the model and share some thoughts

Veeva FY4Q'26 Update

Veeva had a really fine quarter. While the consensus was expecting $811 Million revenue in FY4Q’26, Veeva posted $836 Million revenue. As you can see below, revenue growth of 16% in Q4 comfortably surpassed opex growth of only ~7% which led Veeva to post their highest ever LTM GAAP

Scuttleblurb on Veeva

My friend Scuttleblurb yesterday wrote a very thoughtful piece on Veeva (link to his Website, and Substack). With his permission, I want to highlight three specific bits from his piece. First, Scuttleblurb explained Veeva’s myriad products through the lens of a typical clinical workflow which I thought was really

The Great SaaS Debate

Software is having one of its periodic identity crises. Instead of writing yet another think piece on the future of SaaS, let me curate today a wide range of point of views that I came across on this debate which I think will help you think through the high pitched

"File over App", Veeva at JPM Healthcare Conference

Back in 2023, Steph Ango, CEO of Obsidian, wrote an intriguing piece titled “File over app”. It’s a bit philosophical piece. Some excerpt from the piece: “File over app is a philosophy: if you want to create digital artifacts that last, they must be files you can control, in

Software in Crosshairs: Part 2

After publishing “Software in Crosshairs” last week, I received some interesting feedback. One email from someone who works in enterprise SaaS stood out as he took bit of an issue with how Foundation Capital outlined incumbent companies’ inability to capture the context graphs. I am publishing his email with his

Veeva's Opportunity in Clinical Software

In my Veeva update a couple of days go, I highlighted the below chart to make the point that Veeva clearly expects clinical segment to be their major growth opportunity in their journey to reach $6 Billion revenue run-rate by 2030. Given that context, I wanted to deepen my